Scientific Tracks & Subject Taxonomy
Comprehensive academic classification for proffered abstracts, podium defenses, and clinical symposia. Proffered manuscripts are evaluated under double-blind peer review and categorized across five primary translational disciplines.
Novel Bioconjugation Chemistries & Cleavable Linker Design
Focuses on bioorthogonal conjugation reactions, structural linker stabilization, and controlled Drug-to-Antibody Ratio (DAR) engineering to maximize systemic circulation half-life while preventing premature payload detachment in human plasma.
Site-Specific Conjugation Platforms
Enzymatic transglutaminase labeling, engineered unnatural amino acids, and cysteine-rebridging architectures achieving homogenous DAR 2, 4, and 8 profiles.
Hydrophilicity & Pharmacokinetic Modulators
Polyethylene glycol (PEG) branches, polar carbohydrate shields, and polysarcosine spacers overcoming payload-induced aggregation and rapid hepatic clearance.
Enzyme- & Lysosome-Cleavable Mechanisms
Cathepsin B-cleavable valine-citrulline (Val-Cit) and valine-alanine (Val-Ala) linkers, glucuronide-cleavable designs, and self-immolative spacer kinetics.
Conditional Microenvironment Release
Tumor microenvironment-activated linkers responding to acidic intratumoral pH, hypoxia gradients, and extracellular matrix metalloproteinases (MMPs).
Next-Gen Warheads & Payload Modalities
Addresses the transition beyond classic tubulin inhibitors (MMAE/DM1) toward high-potency Topoisomerase I inhibitors, targeted degradation actuators, immune-modulating warheads, and dual-targeted bispecific conjugates.
Topoisomerase I Inhibitors & Camptothecins
Deruxtecan (DXd) and SN-38 derivatives, optimizing intracellular retention, bystander killing kinetics, and overcoming multi-drug resistance (MDR1) efflux pumps.
Degrader-Antibody Conjugates (DACs)
Targeted delivery of PROTACs and molecular glues via antibody scaffolds to selectively degrade undruggable oncogenic transcription factors and kinases.
Immune-Stimulating Payloads (ISACs)
STING agonists, TLR7/8 agonists, and RIG-I modulators conjugated to turn immunologically "cold" solid tumors "hot" without inducing systemic cytokine release storms.
Bispecific & Biparatopic ADC Architectures
Dual-antigen targeting to enhance internalization velocity, overcome single-target downregulation, and achieve high solid-tumor selectivity over normal tissue.
Targeted Alpha Therapies (TAT) & Radioligand Engineering
Dedicated to high linear energy transfer (LET) alpha-emitting radionuclides. Covers stable cage macrocycles, recoil daughter retention, small-molecule and peptide pharmacokinetic matching, and double-strand DNA cluster break radiobiology.
Actinium-225 (225Ac) Chelation Platforms
DOTA modifications, crown ethers (Macropa), and novel eighteen-membered chelating rings achieving rapid radiolabeling kinetics at mild ambient temperatures.
Lead-212 (212Pb) & In Vivo Alpha Generators
TCMC and cyclen-based chelator chemistry, managing Bismuth-212 daughter emissions, and exploiting Lead-212's favorable 10.6-hour therapeutic half-life.
Astatine-211 (211At) & Halogen Chemistry
Aromatic Astato-demetalation reactions, neopentyl glycol stabilizers, and mitigating in vivo deastatination to prevent thyroid and stomach radiation uptake.
Peptide & Nanobody Carrier Optimization
Designing low-molecular-weight carriers for rapid tumor infiltration and fast renal transit to avoid alpha-induced bone marrow exposure.
Clinical Theranostics & Dual-Action Imaging
Bridges the clinic and the imaging suite. Evaluates diagnostic stratification paired with beta and alpha therapy (e.g., Gallium-68/Lutetium-177, Copper-64/Copper-67), patient-tailored dosimetry, and multicenter solid tumor trial designs.
68Ga / 177Lu Theranostic Pairs in Solid Tumors
Clinical response metrics in PSMA, FAPI, and SSTR-expressing tumors; optimizing administration intervals, pre-treatment imaging criteria, and salvage therapy protocols.
Quantitative 3D Voxel-Based Dosimetry
SPECT/CT and PET/CT internal radiation dose calculations, assessing individual biological effective doses (BED) to avoid arbitrary standard-activity administration.
Renal & Bone Marrow Radioprotection
Basic amino acid co-infusion strategies, gelatin-plasma expanders, and pharmacological nephroprotective adjuvants to widen the maximum tolerated activity (MTA).
Combination Protocols: Radioligands + ADCs / IO
Evaluating radiation-induced antigen upregulation, synergy between targeted radionuclide radiation and immune checkpoint blockade, and sequence-dependent trial outcomes.
Radioisotope Supply Chain, GMP Production & Safety Toxicology
Addresses the acute manufacturing bottlenecks confronting radiopharmaceutical expansion: isotope supply security, hot-cell automation, GMP quality release, regulatory CMC validation, and clinical translation toxicology.
Actinium-225 Production Routes
Thorium-229 generator milking, high-energy proton spallation of Thorium-232, and cyclotron irradiation of Radium-226; addressing isotopic purity and Actinium-227 contamination limits.
Automated Hot-Cell Radiosynthesis & QC
Microfluidic cassettes, robotic dispensing systems, rapid analytical release methods for short-lived radioisotopes, and compliance with Annex 1 sterile manufacturing regulations.
Radiolytic Degradation & Formulation Stability
Radical scavengers (ascorbic acid, gentisic acid, ethanol) and carrier protein stabilizers to prevent self-radiolysis and linker fragmentation during cold-chain shipping.
Radiation Safety, Waste Management & Regulatory CMC
Hospital radioactive waste storage, patient release clearance criteria, and harmonized cross-border radiopharmaceutical transportation regulations (IAEA / Euratom / US NRC).
Proffered Abstract Submission Standards
Every submission must adhere to the editorial guidelines established by the Review Directorate to qualify for double-blind peer review and conference proceedings indexing.
Abstract texts must omit author names, institutional affiliations, and commercial brand identifiers within the abstract body to preserve blind evaluation integrity.
Maximum 350 words structured into four distinct headings: Background & Aim, Methods & Chemistries, Results & Data, and Conclusions & Translational Impact.
Manuscripts are assigned to collegiate review teams immediately upon intake, with formal editorial determinations delivered within 10 business days.
Top-ranked submissions are designated for 15-minute Plenary Podium Defenses; all approved scientific studies are allocated to the Dedicated Poster Walk.